Akcea Therapeutics Inc (AKCA.OQ)
23 May 2019
March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.
ZURICH Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
* Novartis aims to build up heart drug portfolio (Adds comment from Novartis drug developer, details of payment and deal)
BRIEF-Akcea Therapeutics Says Co Will Receive A $150 Mln License Fee That Will Be Split Equally With Ionis
* AKCEA-APO(A)-LRX ADVANCES AS LEADING PHARMACEUTICAL COMPANY EXERCISES OPTION TO LICENSE